Keywords: Eli Lilly, Incyte, JAK1/JAK2, Inflammatory disease, Autoimmune disease, PDL Pharma, Teplizumab, Diabetes

Lilly gains global rights to Incyte's novel JAK1/JAK2 inhibitor for $90 million upfront and up to $665 million more; deal with PDL

Article | 22 December 2009

Print This

US firm Incyte saw its shares rise 5% to $8.92 after announcing it had entered into an exclusive worldwide license and collaboration ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in